HCAT - Health Catalyst, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
42.94
-0.72 (-1.65%)
At close: 4:00PM EDT

43.05 +0.11 (0.26%)
After hours: 4:22PM EDT

Stock chart is not supported by your current browser
Previous Close43.66
Open44.38
Bid42.95 x 1100
Ask44.41 x 1100
Day's Range41.66 - 44.87
52 Week Range36.29 - 49.85
Volume466,324
Avg. Volume791,960
Market Cap1.506B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-39.75
Earnings DateAug 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    Health Catalyst Reports Second Quarter 2019 Results

    SALT LAKE CITY, Aug. 22, 2019 -- Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today.

  • MarketWatch

    Health Catalyst's stock surges as Wall Street analysts unanimously start coverage with bullish ratings

    Shares of Health Catalyst Inc. ran up 5.0% in afternoon trading Monday, after the Wall Street analysts who started coverage of the health data and analytics company were unanimously bullish. The company went public on July 25 at an initial public offering price of $26. Since closing that day at $39.17, the stock has now rallied 14%. In comparison, the Renaissance IPO ETF has shed 6.1% over the same time and the S&P 500 has declined 2.6%. All 7 analysts surveyed by FactSet who started covering Health Catalyst have the equivalent of buy ratings, while the average price target of $50.67 is 14% above current levels. Analyst Anne Samuel at J.P. Morgan, who initiated the company at overweight with a $50 stock price target, said Health Catalyst has less than 5% penetration of an $8 billion addressable market, "leaving significant runway for growth." SunTrust Robinson Humphrey's Sandy Draper started the company at buy with a $53 stock price target, citing an expected "long runway for growth," reinforced by an attractive revenue mix shift that should help improve gross margin as revenue grows.

  • PR Newswire

    Health Catalyst Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    SALT LAKE CITY , July 30 , 2019 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, ...

  • PR Newswire

    Health Catalyst Announces Pricing of Initial Public Offering

    SALT LAKE CITY , July 25, 2019 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, ...

  • Benzinga

    Health Catalyst IPO: What You Need To Know

    Salt Lake City, Utah-based Health Catalyst, Inc. plans to offer 7 million shares in an IPO to be priced between $24 and $25, according to a S-1/Afiling done on July 23. The company upsized the offering from the initially planned 6 million share as well as hiked the estimated price range from $20 to $23. The company's shares have been approved for listing on the Nasdaq under the ticker symbol HCAT.

  • Benzinga

    IPO Outlook For The Week: Biotech, Health Analytics, Sports And Solar Power

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Castle Biosciences Inc (NASDAQ: CSTL ) will issue more than 3.33 million ...